Home/Kamari Pharma/Dayana Michel, MD

DM

Dayana Michel, MD

SVP Medical and Clinical Affairs

Therapeutic Areas

Dermatology Rare Diseases

Kamari Pharma Pipeline

Drug	Indication	Phase
KM-001	Palmoplantar Keratoderma, Olmsted Syndrome, Ichthyosis	Phase 1
KM-023	Severe Keratoderma and Ichthyosis	Preclinical

Leadership Team at Kamari Pharma

David Aviezer, PhD, MBA

Liora Braiman, PhD

Chief Scientific Officer

Asaf Yarkoni, CPA

Chief Financial Officer

View full Kamari Pharma profile